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Available online 11 July 2018Background: Single-dose mebendazole is widely used in preventive chemotherapy against the soil-transmitted
helminths (STHs) Ascaris lumbricoides, hookworm and Trichuris trichiura, yet it shows limited efﬁcacy against
hookworm and T. trichiura infections. The use of adapted treatment regimensmight provide a strategy to control
and eliminate STH infections in STH-persistent settings.We evaluated the safety and efﬁcacy of themultiple dose
mebendazole regimen (3 days 100 mg bid) versus a single dose of 500 mg mebendazole in a setting with high
STH prevalence and high drug pressure.
Methods: This randomised, double-blind clinical trial took place in a primary school on Pemba Island, Tanzania, in
school-aged children (6–12 years). Using a computer random number generator (block size 10), hookworm-
positive children were randomly assigned (1:1) to either a single or multiple dose regimen of mebendazole by
an independent statistician. Two stool samples were collected at baseline and follow-up (18 to 22 days after
treatment) for Kato-Katz analysis. The primary outcome was cure rate (CR) against hookworm. Secondary out-
comes were egg reduction rate (ERR) against hookworm, CRs and ERRs against A. lumbricoides and T. trichiura,
and tolerability assessed 3, 24 and 48 h post-treatment. Participants, investigators, caregivers, outcome assessors
and the trial statistician were blinded. This trial is registered with ClinicalTrials.gov, number NCT03245398.
Findings: 93 children were assigned to each treatment arm. 185 children completed treatment and provided
follow-up stool samples. CR against hookworm was signiﬁcantly higher in the multiple dose (98%) than in the
single dose arm (13%, OR 389.1, 95% CI 95.2 to 2885.7%, p b 0.001). 34 and 42 children reported mild adverse
events in the single andmultiple dose arms, respectively. Themost common events were abdominal pain, head-
ache and diarrhoea.
Interpretation: The poor performance of single dose mebendazole against hookworm infections was conﬁrmed,
but the multiple dose treatment regimen of mebendazole showed high efﬁcacy. Hence, multiple dose
mebendazole might provide a treatment strategy in given epidemiological situations to boost control and elim-
ination of STH infections.
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td. This is an© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
An estimated 472 million people are infected with hookworms
(Ancylostoma duodenale and Necator americanus). Hookworm disease
burden is mainly associated with anaemia, which can cause bothInfection Biology,
itzerland.
open access article undphysical and intellectual growth retardation among preschool- and
school-aged children [1]. In 2016, 1.6 million DALYs were estimated to
be caused by hookworm infections [2], leading to annual productivity
losses of up to US$139 billion [3].
Currently, the control of hookworm and other soil-transmitted hel-
minths is based on periodic deworming (so called preventive chemo-
therapy) of school-aged children and other high-risk groups by
regularly administering a single dose of either albendazole (400 mg)
ormebendazole (500mg) [4]. Both drugs are highly effective against As-
caris lumbricoides but show poor performance against Trichuris trichiura
when administered as a single dose [5]. Moreover, based on a recent
systematic review and network meta-analysis, a single dose ofer the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Research in context
Evidence before this study
We searched in PubMed for all articles published before June 1,
2017 which mentioned both “hookworm” and “mebendazole” in
the abstract, with no language restrictions. Although several stud-
ies have investigated the effect of either a single or a multiple dose
of mebendazole, we only identified one open-label clinical trial,
which compared the effect of both the single and themultiple dose
mebendazole regimen 16 years ago, prior to commencement of
large-scale administration of anthelminthic drugs.
Added value of this study
This is the first double-blind randomised clinical trial comparing the
effect of a single dose (500mg) to amultiple dose (100mg twice a
day during three consecutive days) of mebendazole against hook-
worm infections in Pemba, Tanzania, a settingwith high drug pres-
sure and persistent high hookworm prevalence. The results of this
study clearly showed that the multiple mebendazole dose is more
effective than the single dose. Both regimens were safe with only
mild adverse events being reported.
Implications of all the available evidence
Currently, the main control strategy against hookworm and other
soil-transmitted helminths is preventive chemotherapy, which is
based on the administration a single dose of either mebendazole
or albendazole. Our study confirms that the curative effect of a sin-
gle dose mebendazole is not sufficient for treating hookworm in-
fections and that alternative, more effective treatments, as a
multiple dose mebendazole regimens might be considered, in par-
ticular in persistent hotspot settings.
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while a single dose ofmebendazole fails to clearmost of these infections
(CR = 33%) [5]. The main anthelmintic drugs available to the control
programmes are, therefore, variably efﬁcacious depending on the drug
and parasite. Additionally, there are worries that drug resistance will
emerge, a problem commonly described in veterinary medicine [6].
With preventive chemotherapy being the predominant tool for helmin-
thiasis control, it might not be surprising that soil-transmitted helmin-
thiasis persists in many settings. As an example, recent studies on
Pemba Island reported that prevalence of hookworm continues to
range at high levels from 36 to 97% [7–9], despite regular treatment of
school-aged children. Therefore, additional strategies are required to
control and eliminate soil-transmitted helminth infections, including
access to improvedwater, sanitation and hygiene [1], aswell as adapted
treatment regimens, such as optimised dosing or combination chemo-
therapy which would improve drug therapy.
A multiple dose (100 mg twice per day over three consecutive
days) treatment of mebendazole is recommended globally and in
Tanzania for individual treatment [10–12]. However, surprisingly,
only a few small studies have evaluated the multiple dose regimen
of mebendazole. Moreover, results obtained varied considerably
with cure rates (CRs) ranging from 31 to 100% and, therefore, did
not allow drawing ﬁnal treatment recommendations [13–15]. Fi-
nally, only a single study evaluated both treatment arms in an
open label trial design, more than 15 years ago [14]. No high quality
clinical trial conducted to date did a side-by-side comparison of
multiple dose versus single dose treatment of mebendazole. Thus,
the present trial is, to our knowledge, the ﬁrst randomised,
double-blind trial comparing the efﬁcacy and safety of a single
dose (500 mg) to a multiple dose (six doses of 100 mg over threeconsecutive days twice per day) regimen of mebendazole against
hookworm.2. Methods
2.1. Study Design and Participants
This randomised, double-blind clinical trial was conducted at Piki
Primary School, on Pemba Island, Tanzania, from July 24 to September
15, 2017.
Prior to the study initiation, ethical approval was obtained from the
Zanzibar Medical Research and Ethical Committee (ZAMREC, reference
number 0002/May/17) and from the Ethics Committee of Northern and
Central Switzerland (EKNZ, reference number 2017-00320). This trial is
registered with ClinicalTrials.gov, number NCT03245398.
Before enrolment, all caregivers of children aged 6–12 years attend-
ing the primary school of Piki village were invited to information ses-
sions at school during which the research staff explained the purpose
and procedures of the study, as well as the beneﬁts and potential risks
of participating. Caregivers had the chance to clarify any questions
they may had before they were asked whether they wanted their
child to be included in the study or not. Caregivers who chose to allow
the participation of their child were asked to sign a written informed
consent. Illiterate caregivers provided a thumbprint while an impartial
witness signed to verify that all information in the informed consent
form was conveyed appropriately.
Consenting children were eligible if they had provided two stool
samples, were positive for hookworm eggs in the stool (≥100 eggs per
gram [EPG] or at least two Kato-Katz thick smears slides with more
than one hookworm egg). After the initial clinical examination, children
were excluded from the trial if any of the following exclusion criteria
were present: had menarche (for females); presence of severe anaemia
(haemoglobin b8.0 g/dl was considered severe anaemia); had any
known or reported history of chronic illness such as cancer, diabetes,
chronic heart, liver or renal disease; received any recent anthelminthic
treatment (within past 4 weeks); had any known allergy to
mebendazole or albendazole.2.2. Randomisation and Masking
The trial statistician (JH), who was not involved in any ﬁeld work,
provided a computer-generated stratiﬁed (by baseline infection intensi-
ties) block randomisation code (blocks of size ten). Participantswere al-
located 1:1 to one of the two treatment arms: single dose (500 mg) or
multiple dose (100 mg twice a day during three consecutive days) of
mebendazole. 500 mg and 100 mg mebendazole tablets were obtained
from Johnson & Johnson (Zug, Switzerland). Matching placebos were
manufactured at the University of Basel (100 mg mebendazole
matching placebo) or purchased at Fagron, Germany (500 mg
mebendazole matching placebo). Trial medications were prepared in
advance in identical plastic envelopes labelled with the children's
unique treatment identiﬁcation numbers and sealed. The treatment
lasted 3 days and children received tablets at six different time points
(mornings and evenings of each of the 3 days). At the ﬁrst time point,
all participants received two tablets: either 500 mg mebendazole plus
100 mg mebendazole matching placebo, or 500 mg mebendazole
matching placebo and 100 mg mebendazole; at the remaining ﬁve
time points, children only received one tablet: either 100 mg
mebendazole or matching placebo, depending to which treatment
arm they were allocated. Participants, investigators, caregivers, out-
come assessors and the trial statistician were blinded. Allocation was
concealed: the envelopes containing the drugs were in bags of ten
and, within each group of ten, envelopes were stacked on each other,
preventing the administrator from seeing the next envelope.
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The name, age, sex and school grade of eligible children were re-
corded. Children received containers labelledwith their unique identiﬁ-
cation number (ID) and were asked to provide two stool samples,
preferably on consecutive days. Stool samples were transferred to the
Public Health Laboratory Ivo de Carneri where duplicate Kato-Katz
thick smear slideswere prepared fromeach sample [16]. Slideswere ex-
amined by experienced laboratory technicians under a lightmicroscope
within 1 h after slide preparation, to avoid clearing of hookworm eggs.
Helminth eggs were enumerated and recorded for each parasite (hook-
worm, A. lumbricoides and T. trichiura) separately. To ensure quality of
hookworm diagnosis, 10% of the samples were divided into two stool
containers; one of the containers kept its original participant ID,
whereas the second container was labelled with a new ID (assigned
by the co-investigator). Duplicate Kato-Katz were prepared from both
containers and the ﬁndings compared. Quality control for
A. lumbricoides and T. trichiura consisted of re-reading 10% of all slides.
Any discrepancies between the original and the quality control read
were discussed [17].
All children found positive for hookworm underwent a physical and
clinical examination by a physician. Height was measured with a stan-
dard meter (to the nearest 0.1 cm), weight with an electronic balance
(to the nearest 0.1 kg), and temperature using an electronic ear ther-
mometer (to the nearest 0.1 °C). Haemoglobin levels were measured
in capillary blood using the ﬁnger-prickmethod (HemoCue®301). Chil-
dren were examined for any acute or chronic illness and questioned
about their medical history.
Eligible children were enrolled (by MSP) for treatment which took
place at Piki Primary school during the 3 days following the physical
and clinical examination. Children received treatment with clean
water and a package of biscuits. After everymorning treatment children
were monitored for 3 h and then actively questioned for adverse events
by the study physician and nurses using a questionnaire. The same pro-
cedure took place 24 and 48 h after everymorning treatment. At follow-
up, between 18 to 22 days after treatment, another two stool samples
were collected from each treated child. Participants who remained in-
fected with hookworm, A. lumbricoides and/or T. trichiura at the end of
the study were treated with albendazole (400 mg). Similarly, children
who did not fulﬁl the eligibility criteria but were found infected with
at least one of the parasites during screening were treated with
albendazole.
2.4. Outcomes
The primary outcome of this study was the CR against hookworm
20 days (±3 days) after treatment using the Kato-Katz thick smear
method. CR was deﬁned as percentage of hookworm-positive children
being negative at follow-up. Secondary outcomes were (i) egg reduc-
tion rate (ERR) against hookworm, (ii) CR and ERR against
A. lumbricoides and T. trichiura, and (iii) tolerability (number of adverse
events) assessed 3, 24 and 48 h post-treatment.
An additional secondary outcome, which will not be addressed in
the current manuscript, was caregiver's knowledge related to the clini-
cal trial after attending an information session. This outcome was
assessed using a short questionnaire.
2.5. Sample Size
A CR of 20% was assumed for the single dose mebendazole [9] and a
CR of 40% was assumed for the multiple dose treatment regimen
[18–20]. To detect a difference with 80% power at a two-sided 5% signif-
icance level, a minimum of 79 participants per study armwas required.
Accounting for a loss to follow-up of 12%, we obtained a ﬁnal sample
size of 180 participants (90 per arm).2.6. Statistical Analysis
Datawere double entered by two staffmembers into a database (Ac-
cess 2003, Microsoft) and crosschecked using the Data Compare tool of
EpiInfo version 3.3.2. Any discrepancies between both data entries were
resolved by consulting the original records. Statistical analyses were
performed using STATA 14.0 (StataCorp) and R 3.4.3 (R Development
Core Team). Only children who submitted samples before and after
treatment were included in the available case analysis, which followed
intention to treat principles. Odds ratios (OR)were calculated using un-
adjusted (primary analysis) and adjusted logistic regression (adjust-
ment for age, sex, weight and strata). For ERR calculation, the mean
egg count of the four Kato-Katz thick smears was multiplied by a factor
of 24 to calculate the EPG. ERR was deﬁned as the percentage of mean
reduction at follow-up compared to baseline. ERR was calculated
using both the geometric mean (GM) and the arithmetic mean (AM).
Conﬁdence intervals for ERRs were calculated using the bootstrap re-
sampling method with 5000 replicates. The signiﬁcance level was set
at p-value ≤ 0.05. Infection intensities (light, moderate or heavy) were
determined according to WHO cut-offs [21].
2.7. Role of Funding Source
The funder of the study had input into the study design, but no role
in data collection, data analysis, data interpretation, or writing of the re-
port. The corresponding author had full access to all the data in the
study and had ﬁnal responsibility for the decision to submit for
publication.
3. Results
364 consenting participants were screened for hookworm. 354 chil-
dren provided two baseline stool samples. Of these, 206 were found
hookworm positive andwere invited for the clinical and physical exam-
ination. Two children were excluded because they had haemoglobin
levels below 8.0 g/dl and 18 were absent from school on the clinical
and physical examination day. The remaining 186 children were pres-
ent for treatment and 93 participants were randomly allocated to each
treatment arm. One child from the single dose of mebendazole arm
was lost to follow-up because he/she was not on Pemba Island during
the follow-up period. With the exception of 11 children, who provided
the second baseline stool sample between six and 19 days after the ﬁrst
sample, both stool samples from all other children were collected within
a ﬁve-day window. All remaining 185 participants who provided follow-
up stool samples were included in the available case analysis (Fig. 1).
At the second treatment time point, two children's envelopes were
swapped. Therefore, by the end of the six-treatment time points, one
child had erroneously received 100 mg of mebendazole in addition to
the single dose of 500 mg of mebendazole plus placebo and the other
child received only ﬁve doses instead of six doses of 100 mg of
mebendazole plus 100mg of placebo. These two subjects were included
in the available case analysis but excluded from the per protocol analy-
sis (n = 183) (Appendices 1 and 2). Appendix 3 presents the results of
the analysis using the intention-to-treat population (n = 186).
The treatment arms were balanced according to age, sex, weight,
height, and hookworm baseline infection intensity (Table 1). During
the physical examination, three children were found to have Tinea
capitis, one child reported having asthma and one sickle cell anaemia.
These children were not excluded.
At baseline, among the 354 children who provided two stool sam-
ples, 94.3% of children were infected with at least one soil-transmitted
helminth and 29.4% were co-infected with all three soil-transmitted
helminths. The prevalences of hookworm, A. lumbricoides and
T. trichiurawere 58.2, 36.7 and 92.6%, respectively. In terms of intensity
of infections, 4% of hookworm, 31% of T. trichiura and 45% of
A. lumbricoides infections were moderate or heavy.
Table 1
Baseline characteristics of all randomised children stratiﬁed by treatment arm. Data are n
(%), median (IQR), mean (SD). BMI = body-mass index, EPG = eggs per gram of stool.
Single dose (n = 93) Multiple dose (n = 93)
Mean age (years) 10.1 (1.6) 10.1 (1.6)
Girls 39 (42%) 46 (50%)
Mean weight (kg) 26.7 (5.3) 26.2 (5.1)
Mean height (cm) 132.0 (10.2) 131.8 (9.6)
Mean weight-for-age Z-score −1.4 (1.2) −1.3 (0.8)
Mean height-for-age Z-score −1.1 (1.1) −1.1 (0.7)
Mean BMI-for-age Z-score −1.1 (0.9) −1.2 (0.8)
Hookworm
Infected children 93 (100%) 93 (100%)
Median 222 (78-534) 222 (96-606)
EPG geometric mean 219.0 234.2
Infection intensity
Light (1–1999 EPG) 89 (96%) 90 (97%)
Moderate (2000–3999 EPG) 3 (3%) 3 (3%)
Heavy (≥4000 EPG) 1 (2%) 0
Trichuris trichiura
Infected children 88 (96%) 91 (98%)
EPG geometric mean 661.8 725.7
Infection intensity
Light (1–999 EPG) 59 (66%) 56 (62%)
Moderate (1000–9999 EPG) 30 (34%) 35 (38%)
Heavy (≥10,000 EPG) 0 0
Ascaris lumbricoides
Infected children 47 (51%) 51 (55%)
EPG geometric mean 2691.2 4095.9
Infection intensity
Light (1–4999 EPG) 28 (60%) 20 (39%)
Moderate (5000–49,999
EPG)
15 (32%) 28 (55%)
Heavy (≥50,000 EPG) 4 (8%) 3 (6%)
364 assessed for eligibility
159 excluded
159 did not meet inclusion criteria
18 did not show up for treatment 
93 allocated to single dose mebendazole
92 received allocated intervention
93 allocated to multiple dose mebendazole 
92 received allocated intervention 
186 randomized
92 included in available-case analysis
1 lost to follow-up 
(migration/relocation)
0 lost to follow-up
93 included in available-case analysis
Fig. 1. Trial proﬁle.
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was signiﬁcantly higher (CR = 97.9%) than that of the single dose
(CR = 13.0%, Odds ratio [OR] 303.3, 95% conﬁdence interval [CI]
81.6 to 1999.4, p b 0.001). Superiority was conﬁrmed by the ad-
justed logistic regression model (CR = 13.0% versus CR = 97.8%,
OR 389.1, 95% CI 95.2 to 2885.7%, p b 0.001). In terms of ERR, the
multiple dose (GM ERR= 100.0%) was also signiﬁcantly more effec-
tive than the single dose (GM ERR = 68.0%) (Difference = −0.32,
95% CI −0.46 to −0.22) (Table 2). ERRs obtained with the arith-
metic mean were 99.8% versus 52.7%.
42.9% of children were cured against T. trichiura following six doses
of mebendazole, compared to 6.8% in the single dose arm; this differ-
ence was statistically signiﬁcant (OR 42.9, 95% CI 4.3 to 28.5, p b 0.001
with the unadjusted model; OR 13.4, 95% CI 5.4 to 39.6, p b 0.001 with
the adjusted model). GM ERRs against T. trichiura were 71.7% (95% CI
56.7–78.5) in the single and 98.1% (95% CI 96.8–98.7) in the multiple
dose arm. The corresponding ERRs based on AM were 49.1% and
91.6%, respectively. The single dose of mebendazole cured all children
with an A. lumbricoides infection and the multiple dose cured all but
one child (Table 2). In both arms the ERRs against A. lumbricoides
were N99.9%. Table 3 shows that among the 65 children with moderate
T. trichiura infections at baseline, 10were cured (all in themultiple dose
arm), 43 turned from moderate into light infections (19 in the single
dose arm and 24 in the multiple dose arm), and 11 children remained
atmoderate infection intensity (10 in the single and one in themultiple
dose arm).
At the clinical examination, which took place right before treatment,
a total of 20 children (11.3%) reported symptoms; 10 in the single dose
arm and 10 in the multiple mebendazole dose arm (Appendix 4). The
number of adverse events and children reporting adverse events strati-
ﬁed by treatment arm and evaluation time point are summarised in
Table 4. Children in the multiple dose treatment arm reported slightly
more adverse events than those in the single dose arm. In total, through-
out all adverse event assessment time points, 34 children (37%) in thesingle treatment arm reported symptoms and in the multiple arm 42
children (45%) reported symptoms after treatment (Appendix 4). The
most commonly reported adverse events were abdominal pain (69
Table 4
Number of symptoms reported during the clinical examination and number of children
reporting the symptoms during the clinical examination; number of adverse events
(AEs) reported by children and number of children reporting AEs at each of the AE assess-
ment time points by treatment arm.
Timepoint Number of Single dose
(n = 93)
Multiple dose
(n = 93)
Total
Clinical examination before Symptoms 17 13 30
Table 2
Cure rates (CRs) and egg reduction rates (ERRs) against hookworm, Ascaris lumbricoides
and Trichuris trichiura after the administration of a single or multiple doses of
mebendazole. CR = cure rate, CI = conﬁdence interval, EPG = eggs per gram of stool,
ERR = egg reduction rate.
Single dose Multiple dose
Hookworm
Children positive before treatment 92 93
Children cured after treatment 12 91
CR (95% CI) 13.0% (6.9–21.7) 97.9% (92.4–99.7)
EPG geometric mean
Before treatment 220.2 234.9
After treatment 70.5 0.1
ERR (95% CI) 68.0% (51.5–78.6) 100% (99.9–100)
EPG arithmetic mean
Before treatment 442.6 465.3
After treatment 209.3 1
ERR (95% CI) 52.7% (40.3–63.6) 99.8% (99.3–100)
Trichuris trichiura
Children positive before treatment 88 91
Children cured after treatment 6 39
CR (95% CI) 6.8% (4.6–17.8) 42.9% (33.8–54.8)
EPG geometric mean
Before treatment 655.9 726.8
After treatment 185.5 14.0
ERR (95% CI) 71.7% (56.7–78.5) 98.1% (96.8–98.7)
EPG arithmetic mean
Before treatment 1017.4 1263.8
After treatment 517.6 105.8
ERR (95% CI) 49.1% (31.7–61.0) 91.6% (88.4–94.6)
Ascaris lumbricoides
Children positive before treatment 47 51
Children cured after treatment 47 50
CR (95% CI) 100.0% 98.0% (94.2–100)
EPG geometric mean
Before treatment 2698.5 4113
After treatment 0 0.2
ERR (95% CI) 100.0% 100%
EPG arithmetic mean
Before treatment 14,597.5 14,859.9
After treatment 0 130.9
ERR (95% CI) 100.0% 99.1% (96.9–100)
11M.S. Palmeirim et al. / EClinicalMedicine 1 (2018) 7–13reports), headache (46 reports) and diarrhoea (17 reports) during all
treatment points. All events were mild. A visual examination of the
number of children reporting each type of adverse event throughout
the whole treatment is available in Fig. 2.
4. Discussion
Preventive chemotherapy is the mainstay of helminthiases control,
since it remains among themost cost-effective global public health con-
trol measures [22]. Albendazole and mebendazole, which are variably
efﬁcacious against the different soil-transmitted helminths, are the
most widely used drugs. We were interested in learning whether treat-
ment efﬁcacy could be improved by an adapted treatment regimen in a
setting such as Pemba Island which, even though community members
have been receiving treatment once or twice a year for 25 years [23], isTable 3
Number of children with moderate T. trichiura infections at baseline which, post-treat-
ment, were either cured, evolved into light or heavy infections, or remained with moder-
ate infection intensity.
Post-treatment
infection status
Single
dose
(n = 30)
Multiple dose
(n = 35)
All
(n = 65)
Cured 0 10 10
Evolved into light
infection 19 24 43
No change (remained
with moderate
infection intensity)
10 1 11
Evolved into heavy
infection 1 0 1still characterised by intense helminth transmission and persisting high
prevalence rates [9]. Using a double-blind trial design we evaluated the
multiple dose (3 day, 6 dose course) treatment of mebendazole, which
is recommended globally and in Tanzania for individual treatment
[10–12, 24], versus the single dose regimen widely used for
population-based treatment.
We found clear evidence that the multiple, six-dose treatment
schedule of mebendazole is signiﬁcantly more effective at curing hook-
worm infections than a single dose of mebendazole. In our trial, only
13% of children were cured after a 500 mg single dose of mebendazole.
On the other hand, themultiple dose regimen of mebendazole cured al-
most all hookworm-infected children (CR = 98%) which is in agree-
ment with exploratory studies in the early 1970s [25]. To our
knowledge, only four RCTs, conducted in Iran, Thailand, Brazil and
Papua New Guinea, assessed the effect of the multiple dose
mebendazole on hookworm infections [14, 18–20]. In these studies,
CRs ranged from 35 to 94%. Although these studies reported different
baseline infection intensities, there seems to be no correlation between
the intensity of infection and CRs.
Concerns have been raised that mebendazole resistance had devel-
oped in the setting of Pemba since reduced efﬁcacy of this drug was ob-
served. In more detail, treatment of hookworm infections resulted in
signiﬁcantly lower cure (7.6%) and ERR (52.1%) in 2003 than the ones re-
ported before the beginning of periodic chemotherapy (CR= 22.4%, ERR
=82.4%) [26]. However, our ﬁndings clearly demonstrate thatwith using
the recommended treatment regimen (which does not include dose in-
tensiﬁcation or dose density of chemotherapy, strategies commonly
employed for example in the treatment of cancer [27]) for mebendazole,
high efﬁcacy against hookworm can still be obtained and that specula-
tions ondrug resistance ofmebendazole against hookwormshould there-
fore be considered with caution. On the other hand, it is interesting to
note that the above mentioned strategies of dose intensiﬁcation did not
result in higher efﬁcacy of mebendazole against soil-transmitted hel-
minth infections. For example, RCTs evaluating the effect of 500 mg of
mebendazole daily for 3 days (1500 mg in total) found CRs ranging of
26 to 59% [28, 29]. Thus, the higher dose does not seem to be themost im-
portant determinant driving the drug's effect.
Overall, the hookworm CR for single dose mebendazole we ob-
served on Pemba Island (13%) is in line with results from RCTs con-
ducted in the same setting [9, 26], however is considerably lower
than a CR of 33% calculated from 13 trials in a recent meta-analysis
[5]. This discrepancy between our results and the summary estimatetreatment Children 9 9 18
3 h after 1st morning
treatment
AEs 10 13 23
Children 10 11 21
24 h after 1st morning
treatment
AEs 4 4 8
Children 4 4 8
3 h after 2nd morning
treatment
AEs 12 12 24
Children 6 10 16
24 h after 2nd morning
treatment
AEs 11 13 24
Children 9 9 18
3 h after 3rd morning
treatment
AEs 7 12 19
Children 5 10 15
24 h after 3rd morning
treatment
AEs 9 6 15
Children 7 5 12
48 h after 3rd morning
treatment
AEs 21 28 49
Children 17 22 39
Total during all AE assessment
time points
AEs 91 101 192
Children 34 42 76
Fig. 2. Spider plot indicating the percentage of observed clinical symptoms (before
treatment) and adverse events in both treatment arms (throughout all seven adverse
event assessment time points).
12 M.S. Palmeirim et al. / EClinicalMedicine 1 (2018) 7–13bymeans of meta-analysis could be due to several factors such as the
diagnostic method used, the parasite strain, or the study location:
three of the four RCTs which reported CRs below 20% following a sin-
gle dose of mebendazole against hookworm took place on Pemba Is-
land. Another inﬂuencing factor could be study quality and the
sample size: the two RCTs reporting highest CRs using the single
dose had small sample sizes of 35 and 45 participants in the single
dose mebendazole arms [24, 30].
Our study showed that the multiple dose of mebendazole was also
considerablymore effective against T. trichiura infections than the single
500 mg dose. Not only CRs were higher (CR = 42.9% versus CR = 6.8%
respectively) but moderate infection intensities were less commonly
observed in themultiple dose arm.Our results for themultiple dose reg-
imen against T. trichiura are in line with previous studies conducted in
PapuaNewGuinea and Brazil (CR=65% and CR=39%). However, sim-
ilarly towhatwe found for the efﬁcacy on hookworm, our results for the
single dose were markedly lower than summary estimates reported by
Moser and colleagues (CR = 42%) [5].Unlike the other two parasites, a multiple dose ofmebendazole does
not present an advantage against A. lumbricoides infections over a single
mebendazole dose.
Overall, bothmebendazole treatments were well tolerated. Interest-
ingly, available data on adverse events followingmultiple mebendazole
doses is sparse. None of the three RCTs which tested the efﬁcacy of the
multiple dose mebendazole regimen documented information on ad-
verse events. Headache, abdominal pain or diarrhoea were most com-
monly reported in both treatment arms, which is in line with previous
studies exploring the efﬁcacy and safety of 500 mg mebendazole [24,
31]. In the current study, we found a sudden increase in the number
of adverse events 48 h after the last treatment which is rather unex-
pected due to the short half-life of mebendazole (in the range of 2–
9 h) [32]. For comparison, Speich et al. assessed adverse events at 3,
24, 27 and 48 h post-treatment following a single dose of mebendazole
and found the peak number of symptoms at 24 h [9]. It is important to
highlight that the same trend was observed in both treatment arms
(hence 48 h and 96 h after the last active treatment), which suggests
that this ﬁnding might not be triggered by the treatment but rather by
differences in the reporting.
One limitation of this study is that the Kato-Katz technique has low
sensitivity, particularly for light infections [17]. As an effort to overcome
this limitation, two stool samples were collected on different days and
two slides were prepared from each sample. However, this may still re-
sult in an overestimation of CRs as light infections at follow-up might
have beenmissed and falsely considered as cured. Additionally, the col-
lection of two follow-up samples from 11 children was spaced by more
than 5 days. Although there is no literature on the issue of how many
days between sample collection are recommendable, this could had
some impact on the outcome.
In conclusion, our study has shown that the multiple dose regi-
men of mebendazole is unarguably more effective against hook-
worm and concomitant T. trichiura infections. The ﬁndings of our
study add to recent results demonstrating that adapted treatments,
including improved dosages, regimen or drug combinations consid-
erably increase and broaden the spectrum of activity against soil-
transmitted helminth infections. A multiple dose regimen clearly in-
volves more resources than the administration of a single dose or
drug combinations and comes with additional logistic challenges.
However, in hotspot settings such as Pemba Island where the preva-
lences of hookworm and T. trichiura are so high despite decades of
treatment, this could be a strategy to consider. In the framework of
preventive chemotherapy, drugs are distributed by non-medical
personnel (such as teachers, volunteers or community drug distribu-
tors) in non-medical settings such as schools [33]. Thus, although
more challenging, teachers could provide six doses instead of a single
dose of mebendazole to each school-child. Improved treatments
would trigger a considerable decrease of infections which would
lead to a reduction of reservoirs that sustain reinfections in the pop-
ulation. In parallel, efforts should continue to discover and develop
novel drugs and vaccines, which n the long-term would aid in the
elimination of these diseases [34].
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